Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.49 |
| ▸ | DRD3 | P35462 | 7/20 | 0.49 |
| ▸ | PREP | P48147 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.36 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.36 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3533370 | 0.86 | DRD2 (0.49) | DRD2DRD3PREPKEAP1NFE2L2 | |
| SCHEMBL3528496 | 0.72 | MEN1 (0.45) | DRD2DRD3PREPKEAP1NFE2L2 | |
| SCHEMBL18513311 | 0.67 | HTT (0.68) | KEAP1NFE2L2HTTTGM2MEN1 | |
| SCHEMBL10970250 | 0.66 | HTT (0.63) | KEAP1NFE2L2FAAHHTTTGM2 | |
| SCHEMBL10599151 | 0.65 | HTT (0.68) | KEAP1NFE2L2FAAHHTTTGM2 | |
| SCHEMBL11973884 | 0.65 | HTT (0.68) | KEAP1NFE2L2FAAHHTTTGM2 | |
| SCHEMBL3364812 | 0.65 | HTT (0.68) | KEAP1NFE2L2FAAHHTTTGM2 | |
| SCHEMBL28969063 | 0.65 | HTT (0.68) | KEAP1NFE2L2FAAHHTTTGM2 | |
| SCHEMBL16692630 | 0.65 | HTT (0.68) | KEAP1NFE2L2FAAHHTTTGM2 | |
| SCHEMBL10659971 | 0.65 | HTT (0.68) | KEAP1NFE2L2FAAHHTTTGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742925-B1 | SUBSTITUTED 5, 6, 7, 8-TETRAHYDRO-PYRIDO[4, 3-D]PYRIMIDINE-2-YL COMPOUNDS AND 5, 6, 7, 8-TETRAHYDRO-QUINAZOLINE-2-YL COMPOUNDS | GRUENENTHAL GMBH (DE) | 2014-04-23 | — | — | EP | claimed |
| US-20070249631-A1 | Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds | GRUENENTHAL GMBH (DE) | 2007-10-25 | — | — | US | claimed |
| US-7662828-B2 | Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds | GRUENENTHAL GMBH (DE) | 2010-02-16 | — | — | US | disclosed |
| US-20090176811-A1 | Substituted 5,6,7,8-Tetrahydro-pyrido[4,3-d]pyrimidine-2-yl Compounds and 5,6,7,8-Tetrahydro-quinazoline-2-yl Compounds | GRUENENTHAL GMBH (DE) | 2009-07-09 | — | — | US | disclosed |
| US-20070249631-A1 | Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds | GRUENENTHAL GMBH (DE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249631-A1 | Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds | P2RX7, CYP2C8, P2RX5 | DRD2 1197/4885DRD3 1557/4885PREP 1123/4885 |
| US-20090176811-A1 | Substituted 5,6,7,8-Tetrahydro-pyrido[4,3-d]pyrimidine-2-yl Compounds and 5,6,7,8-Tetrahydro-quinazoline-2-yl Compounds | P2RX7, P2RX5, DPYD | DRD2 1269/4885DRD3 1584/4885PREP 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.